10/555711

JC20 Rec'd PGT/PTO 02 NOV 2005

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jose Luis Castro Pineiro

Int'l Appln.

No. : PCT/GB2004/001926

Int'l Date

Filed: 04 May 2004 (04/05/2004)

Serial No.: (To be assigned) Case No.: T1627P

Filed: November 2, 2005

For : COMBINATION OF A GLYCINE/NMDA

ANTAGONIST AND A TACHYKININ NK-1 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF NEURODEGENERATION

......

Commissioner for Patents Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT 11-02-2005

EXPRESS MAIL NO. <u>EVGGGG9713US</u>

1 HEREBY CERTIFY THAT THIS CORRESPONDENCE IS

BEING BEPOSITED WITH THE UNITED STATES POSTAL

SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"

ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO

COMMISSIONER FOR PATENTS, P.O. BOX 145Q,

ALEXANDRIA, VIRGINIA 22313-1450.

DATE 11-2-

10/555711

Serial No.: Case No.: Page To be assigned T1627P

This Information Disclosure Statement is not an admission that any patent,

publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

JEric Thies

eg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: November 2, 2005

				RZU Recer	Pareur and it rademany Office 11 DEFARTMENT OF COMMERCE	
S	Substitute for form 1449A/PTO			COMPLETE IF KNOWN		
	Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	OSURE	Application Number	10/555711		
c	CTATEMENT DV ADDI ICANIT			Filing Date	November 2, 2005	
STATEMENT BY AFFLICANT			ACANI	First Named Inventor	Jose Luis Castro Pineiro	
			,	Group Art Unit		
	(use as many sheets	as nece	ssary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	T1627P	

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
-								
					-			

			FORE	GN PATENT	DOCUMENTS	•
Examiner Initials*	Cite No.	Foreign Patent Document Office Number		nt Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
			WO 96 09295		Pfizer Ltd	03/28/1996
			WO 98 38186		Pfizer Ltd	09/03/1998
			WO 95 16679		Merck & Co., Inc.	06/22/1995
			·			

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature Date Considered